We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Next Generation Postprocessing Software Receives FDA Clearance

By MedImaging International staff writers
Posted on 05 Jul 2011
A new magnetic resonance (MR) advanced visualization platform has been designed to help clinicians process and analyze images anytime and anywhere.

GE Healthcare (Chalfont St. Giles, UK) announced US Food and Drug Administration (FDA) clearance of Ready View software. Part of the Dexus workflow, Ready View is accessible through any personal computer (PC), picture archiving and communication system (PACS), or radiology information system (RIS) workstation, allowing access to process and analyze images in any office, meeting room or even at home.

The Ready View advanced visualization platform provides a combination of protocols, applications, and advanced tools that enable a fast, easy, and quantified analysis. In addition to standard and advanced protocols, such as four-dimensional (4D) review and image averaging, Ready View offers fast and accurate multiparametric protocols, such as brain oncology, knee, and liver. Multiparametric protocols offer a new, simple, and intuitive workflow to process all functional data from a single screen without having to leave a reading station.

"MR is moving to quantitative analysis to improve lesion detection, characterization, or monitoring," said Jim Davis, general manager, global MR business GE Healthcare. "The Ready View platform is the first step in bringing clinicians a fast and easy way to process and analyze MR data anytime and anywhere. With Ready View, clinicians can automatically segment an abnormality, convert into a 3D volume, then quickly see, and export the curve and associated statistics to the segmented area. "

Combining Ready View's accessibility with its many productivity tools such as autoprocessing, save state, one-click motion correction, and real time thresholding and segmentation, the software will not only help streamline image processing and analysis but help clinicians provide an effective diagnosis.

Related Links:
GE Healthcare




Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
1.5T MRI System
uMR 670
Color Doppler Ultrasound System
DRE Crystal 4PX
Computed Tomography (CT) Scanner
Aquilion Serve SP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to MedImaging.net and get complete access to news and events that shape the world of Radiology.
  • Free digital version edition of Medical Imaging International sent by email on regular basis
  • Free print version of Medical Imaging International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of Medical Imaging International in digital format
  • Free Medical Imaging International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.